Article Text

PDF
Original research
Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
  1. Grant C Sorkin1,2,
  2. Travis M Dumont1,2,
  3. Michael M Wach1,2,
  4. Jorge L Eller1,2,
  5. Maxim Mokin1,2,
  6. Sabareesh K Natarajan1,2,
  7. Melissa S Baxter3,
  8. Kenneth V Snyder1,2,4,5,6,
  9. Elad I Levy1,2,5,6,
  10. L Nelson Hopkins1,2,5,6,7,
  11. Adnan H Siddiqui1,2,5,6
  1. 1Department of Neurosurgery, University at Buffalo, State University of New York, Buffalo, New York, USA
  2. 2Department of Neurosurgery, Gates Vascular Institute, Kaleida Health, Buffalo, New York, USA
  3. 3School of Pharmacy, University at Buffalo, State University of New York, Buffalo, New York, USA
  4. 4Department of Neurology, University at Buffalo, State University of New York, Buffalo, New York, USA
  5. 5Department of Radiology, University at Buffalo, State University of New York, Buffalo, New York, USA
  6. 6Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York, Buffalo, New York, USA
  7. 7Jacobs Institute, Buffalo, New York, USA
  1. Correspondence to Dr A H Siddiqui, Department of Neurosurgery, University at Buffalo, State University of New York, 100 High Street, Suite B4, Buffalo, NY 14203, USA; asiddiqui{at}ubns.com

Abstract

Objective Limited data exist regarding the use of antiplatelet response assays during neuroendovascular intervention. We report outcomes after carotid artery stenting (CAS) based on aspirin and P2Y12 assays.

Methods We retrospectively identified patients who had aspirin and P2Y12 assays at the time of stenting. Aspirin (325 mg) and clopidogrel (75 mg) were started 7–10 days pre-intervention. If not possible, aspirin (650 mg) and clopidogrel (600 mg) loading doses were given pre-intervention. Assays were checked on postoperative day 0/1. Outcomes included neurological ischemic sequela at 30 days, 1 and 2 years, as well as 30 day death/hemorrhage/myocardial infarction.

Results 449 patients were included. Mean P2Y12 reaction unit (PRU) values were higher in patients with an ipsilateral ischemic event (stroke/transient ischemic attack (TIA)) or stroke (alone) at 1 and 2 years than in patients with no events: ischemic event versus no event at 1 year, 252 vs 202 (p=0.008); stroke versus no stroke at 1 year, 252 versus 203(p=0.029); ischemic event versus no event at 2 years, 244 vs 203 (p=0.047); stroke versus no stroke at 2 years, 243 versus 203 (p=0.082). Ischemic event free survival (stroke/TIA, p=0.0268) and overall survival (p=0.0291) post-CAS were longer in patients with PRU ≤198 compared with an initial threshold of PRU ≤237. Mean PRU values were higher in patients who died from all causes at 30 days than in survivors (p=0.031). No correlation was found between lower PRU values and hemorrhage. Aspirin reaction units did not correlate with outcome.

Conclusions PRU ≤198 may be associated with a lower incidence of ischemic neurological sequela and death post-CAS. Prospective studies are needed to validate the relationship between antiplatelet assays and outcomes post-CAS.

  • Drug
  • Platelets
  • Stent
  • Stroke
  • Technique

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.